Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Nurix Therapeutics (NRIX) Return on Capital Employed: 2020-2025

Historic Return on Capital Employed for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to -0.56%.

  • Nurix Therapeutics' Return on Capital Employed fell 11.00% to -0.56% in Q3 2025 from the same period last year, while for Aug 2025 it was -0.56%, marking a year-over-year decrease of 11.00%. This contributed to the annual value of -0.51% for FY2024, which is 1.00% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Return on Capital Employed of -0.56% as of Q3 2025, which was down 28.91% from -0.44% recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Return on Capital Employed ranged from a high of -0.22% in Q2 2021 and a low of -0.64% during Q1 2024.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.56% (2023), whereas its average is -0.53%.
  • As far as peak fluctuations go, Nurix Therapeutics' Return on Capital Employed dropped by 26bps in 2022, and later climbed by 22bps in 2025.
  • Over the past 5 years, Nurix Therapeutics' Return on Capital Employed (Quarterly) stood at -0.28% in 2021, then dropped by 22bps to -0.50% in 2022, then declined by 13bps to -0.63% in 2023, then grew by 20bps to -0.43% in 2024, then decreased by 11bps to -0.56% in 2025.
  • Its Return on Capital Employed was -0.56% in Q3 2025, compared to -0.44% in Q2 2025 and -0.42% in Q1 2025.